NeuroMolecular Medicine

, Volume 16, Issue 1, pp 61–69

Selective Serotonin 3 Receptor Antagonist Treatment for Schizophrenia: Meta-analysis and Systematic Review

  • Taro Kishi
  • Tomohiko Mukai
  • Yuki Matsuda
  • Nakao Iwata
Original Paper

DOI: 10.1007/s12017-013-8251-0

Cite this article as:
Kishi, T., Mukai, T., Matsuda, Y. et al. Neuromol Med (2014) 16: 61. doi:10.1007/s12017-013-8251-0

Abstract

Double-blinded, randomized, placebo-control trials of selective serotonin 3 receptor antagonists (5-HT3R-ANTs) for schizophrenia have differed in outcome. This meta-analysis tests the hypothesis that 5-HT3R-ANTs are effective for the treatment for schizophrenia. We searched PubMed, the Cochrane Library database, and PsycINFO up to June 15, 2013. We conducted a systematic review and meta-analysis of individual patient data from randomized controlled trials comparing 5-HT3R-ANTs add-on therapy with placebo. The risk ratio (RR), 95 % confidence intervals (CI), and standardized mean difference (SMD) were calculated. A random-effects model was used. Six studies (total n = 311) were identified. These included one granisetron plus risperidone study, one ondansetron plus risperidone study, one ondansetron plus haloperidol, and three tropisetron plus risperidone studies. The statistically significant effects of 5-HT3R-ANTs add-on therapy on Positive and Negative Syndrome Scale (PANSS) total scores were SMD = −1.03, CI = −1.70 to −0.36, p = 0.003 (I2 = 82 %, 5 studies, n = 261); on negative scores were SMD = −1.10, CI = −1.82 to −0.39, p = 0.002 (I2 = 84 %, 5 studies, n = 261); and on PANSS general scores were SMD = −0.70, CI = −1.23 to −0.17, p = 0.01 (I2 = 73 %, 5 studies, n = 261). However, 5-HT3R-ANTs add-on therapy was not superior to placebo in PANSS positive scores (SMD = −0.12, p = 0.33). Dropout due to all cause (RR = 0.80, p = 0.50), inefficacy (RR = 0.76, p = 0.65), or adverse events (RR = 0.84, p = 0.75) was similar in both groups. Constipation occurred significantly more often with 5-HT3R-ANTs than placebo (RR = 2.05, CI = 1.07–3.91, p = 0.03, NNH = 11, p = 0.02). 5-HT3R-ANTs add-on therapy is more beneficial on the psychopathology (especially negative symptoms) than controls in patients with schizophrenia, and 5-HT3R-ANTs seem to be well-tolerated treatments.

Keywords

Schizophrenia Serotonin 3 receptor antagonists Meta-analysis Granisetron Ondansetron Tropisetron 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Taro Kishi
    • 1
  • Tomohiko Mukai
    • 1
  • Yuki Matsuda
    • 1
  • Nakao Iwata
    • 1
  1. 1.Department of PsychiatryFujita Health University School of MedicineToyoakeJapan

Personalised recommendations